Catecholaminergic Modulation of Trust Decisions

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2019 Feb 2

PMID 30706097

Authors

Catalina E Ratala

Sean J Fallon

Marieke E van der Schaaf

Niels Ter Huurne

Roshan Cools

Alan G Sanfey

Affiliations

Soon will be listed here.

Abstract

Rationale: Trust is a key component of social interactions. In order to assess the trustworthiness of others, people rely on both information learned from previous encounters, as well as on implicit biases associated with specific facial features.

Objective: Here, we investigated the role of catecholamine (dopamine and noradrenaline) transmission on trust decisions as a function of both experienced behavior and facial features.

Methods: To increase catecholamine levels, methylphenidate (MPH, i.e., Ritalin®, 20 mg) was administered to participants (N = 24) prior to their playing a well-studied economic task, namely the Trust Game (Berg et al. 1995). We measured the amount of money invested with a variety of game partners. Across game partners, we manipulated two aspects of trust: the facial trust level (high facial trust, low facial trust, and non-social) and the likelihood of reciprocation (high, low).

Results: Results demonstrated no main effect of MPH on investments, but rather a selective lowering of investments under MPH as compared with placebo with the game partners who were low on facial trustworthiness and were low reciprocators.

Conclusion: These results provide evidence that MPH administration impacts social trust decision-making, but does so in a context-specific manner.

References

Pessiglione M, Seymour B, Flandin G, Dolan R, Frith C . Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature. 2006; 442(7106):1042-5. PMC: 2636869. DOI: 10.1038/nature05051. View

Chang L, Doll B, van t Wout M, Frank M, Sanfey A . Seeing is believing: trustworthiness as a dynamic belief. Cogn Psychol. 2010; 61(2):87-105. DOI: 10.1016/j.cogpsych.2010.03.001. View

Volkow N, Wang G, Fowler J, Logan J, Franceschi D, Maynard L . Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse. 2002; 43(3):181-7. DOI: 10.1002/syn.10038. View

Shiels K, Hawk L, Reynolds B, Mazzullo R, Rhodes J, Pelham W . Effects of methylphenidate on discounting of delayed rewards in attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol. 2009; 17(5):291-301. PMC: 2908283. DOI: 10.1037/a0017259. View

van der Schaaf M, Fallon S, Ter Huurne N, Buitelaar J, Cools R . Working memory capacity predicts effects of methylphenidate on reversal learning. Neuropsychopharmacology. 2013; 38(10):2011-8. PMC: 3746683. DOI: 10.1038/npp.2013.100. View

Eisenegger C, Naef M, Linssen A, Clark L, Gandamaneni P, Muller U . Role of dopamine D2 receptors in human reinforcement learning. Neuropsychopharmacology. 2014; 39(10):2366-75. PMC: 4138746. DOI: 10.1038/npp.2014.84. View

Frank M, Seeberger L, OReilly R . By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science. 2004; 306(5703):1940-3. DOI: 10.1126/science.1102941. View

Williams L, Hermens D, Palmer D, Kohn M, Clarke S, Keage H . Misinterpreting emotional expressions in attention-deficit/hyperactivity disorder: evidence for a neural marker and stimulant effects. Biol Psychiatry. 2008; 63(10):917-26. DOI: 10.1016/j.biopsych.2007.11.022. View

Arnsten A . Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry. 2011; 69(12):e89-99. PMC: 3145207. DOI: 10.1016/j.biopsych.2011.01.027. View

10.

Ter Huurne N, Fallon S, van Schouwenburg M, van der Schaaf M, Buitelaar J, Jensen O . Methylphenidate alters selective attention by amplifying salience. Psychopharmacology (Berl). 2015; 232(23):4317-23. DOI: 10.1007/s00213-015-4059-y. View

11.

Frank M, Scheres A, Sherman S . Understanding decision-making deficits in neurological conditions: insights from models of natural action selection. Philos Trans R Soc Lond B Biol Sci. 2007; 362(1485):1641-54. PMC: 2440777. DOI: 10.1098/rstb.2007.2058. View

12.

Chang L, Sanfey A . Great expectations: neural computations underlying the use of social norms in decision-making. Soc Cogn Affect Neurosci. 2011; 8(3):277-84. PMC: 3594719. DOI: 10.1093/scan/nsr094. View

13.

Winston J, Strange B, ODoherty J, Dolan R . Automatic and intentional brain responses during evaluation of trustworthiness of faces. Nat Neurosci. 2002; 5(3):277-83. DOI: 10.1038/nn816. View

14.

King-Casas B, Tomlin D, Anen C, Camerer C, Quartz S, Montague P . Getting to know you: reputation and trust in a two-person economic exchange. Science. 2005; 308(5718):78-83. DOI: 10.1126/science.1108062. View

15.

Fallon S, van der Schaaf M, Ter Huurne N, Cools R . The Neurocognitive Cost of Enhancing Cognition with Methylphenidate: Improved Distractor Resistance but Impaired Updating. J Cogn Neurosci. 2016; 29(4):652-663. DOI: 10.1162/jocn_a_01065. View

16.

Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1999; 59 Suppl 20:22-33;quiz 34-57. View

17.

Wardle M, de Wit H . Effects of amphetamine on reactivity to emotional stimuli. Psychopharmacology (Berl). 2011; 220(1):143-53. PMC: 3277682. DOI: 10.1007/s00213-011-2498-7. View

18.

Doll B, Jacobs W, Sanfey A, Frank M . Instructional control of reinforcement learning: a behavioral and neurocomputational investigation. Brain Res. 2009; 1299:74-94. PMC: 3050481. DOI: 10.1016/j.brainres.2009.07.007. View

19.

Singer T, Kiebel S, Winston J, Dolan R, Frith C . Brain responses to the acquired moral status of faces. Neuron. 2004; 41(4):653-62. DOI: 10.1016/s0896-6273(04)00014-5. View

20.

Dolder P, Muller F, Schmid Y, Borgwardt S, Liechti M . Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. Psychopharmacology (Berl). 2017; 235(2):467-479. PMC: 5813072. DOI: 10.1007/s00213-017-4650-5. View